Cargando…

Radiodynamic therapy with CsI(na)@MgO nanoparticles and 5-aminolevulinic acid

BACKGROUND: Radiodynamic therapy (RDT) holds the potential to overcome the shallow tissue penetration issue associated with conventional photodynamic therapy (PDT). To this end, complex and sometimes toxic scintillator–photosensitizer nanoconjugates are often used, posing barriers for large-scale ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Fangchao, Lee, Chaebin, Zhang, Weizhong, Jiang, Wen, Cao, Zhengwei, Chong, Harrison Byron, Yang, Wei, Zhan, Shuyue, Li, Jianwen, Teng, Yong, Li, Zibo, Xie, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288050/
https://www.ncbi.nlm.nih.gov/pubmed/35842630
http://dx.doi.org/10.1186/s12951-022-01537-z
_version_ 1784748379991965696
author Jiang, Fangchao
Lee, Chaebin
Zhang, Weizhong
Jiang, Wen
Cao, Zhengwei
Chong, Harrison Byron
Yang, Wei
Zhan, Shuyue
Li, Jianwen
Teng, Yong
Li, Zibo
Xie, Jin
author_facet Jiang, Fangchao
Lee, Chaebin
Zhang, Weizhong
Jiang, Wen
Cao, Zhengwei
Chong, Harrison Byron
Yang, Wei
Zhan, Shuyue
Li, Jianwen
Teng, Yong
Li, Zibo
Xie, Jin
author_sort Jiang, Fangchao
collection PubMed
description BACKGROUND: Radiodynamic therapy (RDT) holds the potential to overcome the shallow tissue penetration issue associated with conventional photodynamic therapy (PDT). To this end, complex and sometimes toxic scintillator–photosensitizer nanoconjugates are often used, posing barriers for large-scale manufacturing and regulatory approval. METHODS: Herein, we report a streamlined RDT strategy based on CsI(Na)@MgO nanoparticles and 5-aminolevulinic acid (5-ALA). 5-ALA is a clinically approved photosensitizer, converted to protoporphyrin IX (PpIX) in cancer cells’ mitochondria. CsI(Na)@MgO nanoparticles produce strong ~ 410 nm X-ray luminescence, which matches the Soret band of PpIX. We hypothesize that the CsI(Na)@MgO-and-5-ALA combination can mediate RDT wherein mitochondria-targeted PDT synergizes with DNA-targeted irradiation for efficient cancer cell killing. Because scintillator nanoparticles and photosensitizer are administered separately, the approach forgoes issues such as self-quenching or uncontrolled release of photosensitizers. RESULTS: When tested in vitro with 4T1 cells, the CsI(Na)@MgO and 5-ALA combination elevated radiation-induced reactive oxygen species (ROS), enhancing damages to mitochondria, DNA, and lipids, eventually reducing cell proliferation and clonogenicity. When tested in vivo in 4T1 models, RDT with the CsI(Na)@MgO and 5-ALA combination significantly improved tumor suppression and animal survival relative to radiation therapy (RT) alone. After treatment, the scintillator nanoparticles, made of low-toxic alkali and halide elements, were efficiently excreted, causing no detectable harm to the hosts. CONCLUSIONS: Our studies show that separately administering CsI(Na)@MgO nanoparticles and 5-ALA represents a safe and streamlined RDT approach with potential in clinical translation. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01537-z.
format Online
Article
Text
id pubmed-9288050
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92880502022-07-17 Radiodynamic therapy with CsI(na)@MgO nanoparticles and 5-aminolevulinic acid Jiang, Fangchao Lee, Chaebin Zhang, Weizhong Jiang, Wen Cao, Zhengwei Chong, Harrison Byron Yang, Wei Zhan, Shuyue Li, Jianwen Teng, Yong Li, Zibo Xie, Jin J Nanobiotechnology Research BACKGROUND: Radiodynamic therapy (RDT) holds the potential to overcome the shallow tissue penetration issue associated with conventional photodynamic therapy (PDT). To this end, complex and sometimes toxic scintillator–photosensitizer nanoconjugates are often used, posing barriers for large-scale manufacturing and regulatory approval. METHODS: Herein, we report a streamlined RDT strategy based on CsI(Na)@MgO nanoparticles and 5-aminolevulinic acid (5-ALA). 5-ALA is a clinically approved photosensitizer, converted to protoporphyrin IX (PpIX) in cancer cells’ mitochondria. CsI(Na)@MgO nanoparticles produce strong ~ 410 nm X-ray luminescence, which matches the Soret band of PpIX. We hypothesize that the CsI(Na)@MgO-and-5-ALA combination can mediate RDT wherein mitochondria-targeted PDT synergizes with DNA-targeted irradiation for efficient cancer cell killing. Because scintillator nanoparticles and photosensitizer are administered separately, the approach forgoes issues such as self-quenching or uncontrolled release of photosensitizers. RESULTS: When tested in vitro with 4T1 cells, the CsI(Na)@MgO and 5-ALA combination elevated radiation-induced reactive oxygen species (ROS), enhancing damages to mitochondria, DNA, and lipids, eventually reducing cell proliferation and clonogenicity. When tested in vivo in 4T1 models, RDT with the CsI(Na)@MgO and 5-ALA combination significantly improved tumor suppression and animal survival relative to radiation therapy (RT) alone. After treatment, the scintillator nanoparticles, made of low-toxic alkali and halide elements, were efficiently excreted, causing no detectable harm to the hosts. CONCLUSIONS: Our studies show that separately administering CsI(Na)@MgO nanoparticles and 5-ALA represents a safe and streamlined RDT approach with potential in clinical translation. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01537-z. BioMed Central 2022-07-16 /pmc/articles/PMC9288050/ /pubmed/35842630 http://dx.doi.org/10.1186/s12951-022-01537-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jiang, Fangchao
Lee, Chaebin
Zhang, Weizhong
Jiang, Wen
Cao, Zhengwei
Chong, Harrison Byron
Yang, Wei
Zhan, Shuyue
Li, Jianwen
Teng, Yong
Li, Zibo
Xie, Jin
Radiodynamic therapy with CsI(na)@MgO nanoparticles and 5-aminolevulinic acid
title Radiodynamic therapy with CsI(na)@MgO nanoparticles and 5-aminolevulinic acid
title_full Radiodynamic therapy with CsI(na)@MgO nanoparticles and 5-aminolevulinic acid
title_fullStr Radiodynamic therapy with CsI(na)@MgO nanoparticles and 5-aminolevulinic acid
title_full_unstemmed Radiodynamic therapy with CsI(na)@MgO nanoparticles and 5-aminolevulinic acid
title_short Radiodynamic therapy with CsI(na)@MgO nanoparticles and 5-aminolevulinic acid
title_sort radiodynamic therapy with csi(na)@mgo nanoparticles and 5-aminolevulinic acid
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288050/
https://www.ncbi.nlm.nih.gov/pubmed/35842630
http://dx.doi.org/10.1186/s12951-022-01537-z
work_keys_str_mv AT jiangfangchao radiodynamictherapywithcsinamgonanoparticlesand5aminolevulinicacid
AT leechaebin radiodynamictherapywithcsinamgonanoparticlesand5aminolevulinicacid
AT zhangweizhong radiodynamictherapywithcsinamgonanoparticlesand5aminolevulinicacid
AT jiangwen radiodynamictherapywithcsinamgonanoparticlesand5aminolevulinicacid
AT caozhengwei radiodynamictherapywithcsinamgonanoparticlesand5aminolevulinicacid
AT chongharrisonbyron radiodynamictherapywithcsinamgonanoparticlesand5aminolevulinicacid
AT yangwei radiodynamictherapywithcsinamgonanoparticlesand5aminolevulinicacid
AT zhanshuyue radiodynamictherapywithcsinamgonanoparticlesand5aminolevulinicacid
AT lijianwen radiodynamictherapywithcsinamgonanoparticlesand5aminolevulinicacid
AT tengyong radiodynamictherapywithcsinamgonanoparticlesand5aminolevulinicacid
AT lizibo radiodynamictherapywithcsinamgonanoparticlesand5aminolevulinicacid
AT xiejin radiodynamictherapywithcsinamgonanoparticlesand5aminolevulinicacid